High-Level Overview
Corify Care is a biomedical technology company developing ACORYS, a non-invasive, AI-powered cardiac mapping system that creates real-time, beat-to-beat electroanatomic maps of the entire heart in under 10 minutes using 128 body-surface sensors.[1][2][5] It serves clinicians treating patients with cardiac arrhythmias, particularly atrial fibrillation (AFib) affecting over 30 million worldwide, by enabling precise diagnosis, personalized ablation guidance, and reduced procedure risks, times, and costs—addressing failures in over 50-60% of complex cases.[2][3][4] Growth momentum includes €6M in recent funding for European scaling, CE Mark under MDR in July 2024, over 1,000 patients in clinical trials, Mayo Clinic collaboration (May 2025), and pending FDA approval for U.S. entry.[3][4]
Origin Story
Founded in 2019 as a spin-off from Universitat Politècnica de València, Corify Care originated from research at Hospital Universitario Gregorio Marañón in Madrid and the university, combining high-density hardware with AI algorithms for arrhythmia mapping.[1][2] Key founders include biomedical engineers Andreu Climent (current CEO) and María Guillem, alongside renowned cardiologists Felipe Atienza and Francisco Fernández-Avilés.[2] Early traction came from EIT Health support, winning the EIT Innovation Award in 2020, preliminary validation with 150+ patients in Spain and the U.S., and the €2.5M SAVE-COR project funding clinical trials across Spain and Portugal.[1][2][4] These milestones propelled regulatory progress and market readiness.
Core Differentiators
- Non-invasive, real-time mapping: Unlike invasive catheter-based or imaging-dependent methods (CT/MRI), ACORYS uses body-surface sensors for global, beat-to-beat heart views in <10 minutes, without radiation or lengthy setups.[1][3][4][5]
- AI-driven precision: Algorithms detect pathological electrical patterns, create 3D electroanatomic maps, and guide ablations, boosting success rates and cutting recurrence risks for AFib, ventricular tachycardia, and resynchronization therapy.[1][2][3]
- Efficiency and accessibility: Reduces procedure complexity, time, and costs (e.g., €13.5B wasted in Europe on repeat AFib ablations); validated in 1,000+ patients with CE Mark achieved.[2][4]
- Evolving ecosystem: Backed by EIT Health network; recent Mayo Clinic partnership refines usability; ACORYS 2.0 in development with digital twins for hyper-personalized care.[3][4]
Role in the Broader Tech Landscape
Corify Care rides the wave of AI in precision cardiology, targeting the exploding AFib epidemic—10.7M patients in Europe now, projected to 2% of population by 2050 amid aging demographics and rising cardiovascular disease.[2][4] Timing aligns with regulatory shifts like Europe's MDR and U.S. FDA pathways, plus post-pandemic demand for non-invasive, efficient diagnostics amid €13.5B+ annual waste from failed ablations.[2][4] Market tailwinds include EIT Health's innovation ecosystem and clinician adoption needs for complex cases (50%+ failure rates).[3][4] It influences the field by pioneering "imageless ECGI," enabling outpatient mapping, reducing invasiveness, and setting standards for AI-personalized cardiac interventions, potentially saving millions of lives globally.[1][3]
Quick Take & Future Outlook
Corify Care is poised for explosive growth with U.S. FDA clearance imminent, €6M fueling ACORYS deployment across Europe, and Mayo Clinic enhancing clinical integration—positioning it as a global leader in arrhythmia care.[3][4] Trends like AI-digital twins, expanded indications (e.g., pacemakers), and value-based healthcare will accelerate adoption, especially as AFib burdens healthcare systems. Its influence may evolve from disruptor to standard-of-care provider, revolutionizing treatments for 60M+ patients and exemplifying university spin-offs' impact, much like its origins promised: quick, accurate, safe cardiac mapping to save hearts.[1][5]
